Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 04:00PM ET
0.7090
Dollar change
+0.0490
Percentage change
7.42
%
Index- P/E- EPS (ttm)-2.96 Insider Own49.70% Shs Outstand27.43M Perf Week28.91%
Market Cap19.52M Forward P/E- EPS next Y-2.02 Insider Trans-0.04% Shs Float13.85M Perf Month6.62%
Income-81.22M PEG- EPS next Q-0.55 Inst Own15.45% Short Float0.24% Perf Quarter-34.35%
Sales0.00M P/S- EPS this Y15.22% Inst Trans-5.85% Short Ratio0.17 Perf Half Y-75.38%
Book/sh1.91 P/B0.37 EPS next Y26.19% ROA-69.04% Short Interest0.03M Perf Year-80.36%
Cash/sh2.17 P/C0.33 EPS next 5Y- ROE-90.85% 52W Range0.49 - 3.71 Perf YTD28.91%
Dividend Est.- P/FCF- EPS past 5Y- ROI-133.33% 52W High-80.89% Beta-0.32
Dividend TTM- Quick Ratio3.81 Sales past 5Y0.00% Gross Margin- 52W Low44.69% ATR (14)0.08
Dividend Ex-Date- Current Ratio3.81 EPS Y/Y TTM5.23% Oper. Margin0.00% RSI (14)58.54 Volatility9.93% 12.82%
Employees89 Debt/Eq0.27 Sales Y/Y TTM- Profit Margin- Recom1.33 Target Price5.50
Option/ShortNo / Yes LT Debt/Eq0.16 EPS Q/Q15.76% Payout- Rel Volume1.74 Prev Close0.66
Sales Surprise- EPS Surprise24.46% Sales Q/Q- EarningsNov 09 AMC Avg Volume201.39K Price0.71
SMA2014.84% SMA509.21% SMA200-62.96% Trades Volume351,383 Change7.42%
Date Action Analyst Rating Change Price Target Change
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Feb-28-24 04:01PM
Jan-31-24 04:01PM
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
12:00PM Loading…
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
04:05PM Loading…
Apr-03-23 04:05PM
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
07:30AM Loading…
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Atlas Venture Fund XI, L.P.10% OwnerFeb 08Sale0.647334692,019,563Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerFeb 08Sale0.64267171734,546Feb 09 04:33 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12Sale0.831,5401,2782,020,296Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 12Sale0.83560465734,813Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11Sale0.871,5661,3622,021,836Jan 16 06:16 PM
Atlas Venture Fund XI, L.P.10% OwnerJan 11Sale0.87569495735,373Jan 16 06:16 PM